2004
Gender, Social Support, and Posttraumatic Stress in Postwar Kosovo
Ahern J, Galea S, Fernandez W, Koci B, Waldman R, Vlahov D. Gender, Social Support, and Posttraumatic Stress in Postwar Kosovo. The Journal Of Nervous And Mental Disease 2004, 192: 762-770. PMID: 15505520, DOI: 10.1097/01.nmd.0000144695.02982.41.Peer-Reviewed Original ResearchConceptsPosttraumatic stress scoresPosttraumatic stress symptomsSocial supportStress scoresImportant public health effortsEmergency department studyEmergency department patientsMental health 2 yearsTraumatic eventsPublic health effortsLower posttraumatic stress scoresGreater protective effectStress symptomsLow social supportMore traumatic eventsDepartment patientsHigh prevalenceProtective effectHealth effortsHigher posttraumatic stress scoresDepartment studyMental healthWomenPosttraumatic stressSymptoms
2000
Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART
Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y, Group T. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug And Alcohol Dependence 2000, 60: 51-54. PMID: 10821989, DOI: 10.1016/s0376-8716(00)80007-1.Peer-Reviewed Original ResearchConceptsEfficacy of HAARTDrug usersBuprenorphine substitution treatmentViral load trendsActive antiretroviral therapyFrench cohort studyHIV viral loadUse of buprenorphineInjection drug usersVirologic responseAntiretroviral therapyCohort studyBuprenorphine treatmentTreatment initiationViral loadMaintenance treatmentPotential confoundersHAARTSubstitution treatmentBuprenorphineHIVIndividual treatmentPatientsTreatmentLinear regression models
1999
New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users
Krol A, Flynn C, Vlahov D, Miedema F, Coutinho R, van Ameijden E. New evidence to reconcile in vitro and epidemiologic data on the possible role of heroin on CD4+ decline among HIV-infected injecting drug users. Drug And Alcohol Dependence 1999, 54: 145-154. PMID: 10217554, DOI: 10.1016/s0376-8716(98)00158-6.Peer-Reviewed Original Research
1998
Vitamin A Supplementation and Human Immunodeficiency Virus Load in Injection Drug Users
Semba R, Lyles C, Margolick J, Caiaffa W, Farzadegan H, Cohn S, Vlahov D. Vitamin A Supplementation and Human Immunodeficiency Virus Load in Injection Drug Users. The Journal Of Infectious Diseases 1998, 177: 611-616. PMID: 9498439, DOI: 10.1086/514235.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHigh-dose vitaminHIV loadInjection drug usersLymphocyte countDrug usersVitamin AHuman immunodeficiency virus (HIV) infectionPlacebo-controlled clinical trialHuman immunodeficiency virus loadImmunodeficiency virus infectionUse of vitaminsPlasma vitaminHIV replicationVirus loadClinical trialsVirus infectionClinical investigationRetinol equivalentsSupplementationRetinoic acid response elementVitaminWeeksAcid response elementCount
1997
The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users
Lyles C, Margolick J, Astemborski J, Graham N, Anthony J, Hoover D, Vlahov D. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users. AIDS 1997, 11: 1255-1262. PMID: 9256944, DOI: 10.1097/00002030-199710000-00009.Peer-Reviewed Original ResearchConceptsRate of CD4Lymphocyte countLymphocyte declineDrug use patternsDrug usersRate of declineDrug useMedian initial CD4Episodes of withdrawalSpecific drug typesDrug use variablesDrug use practicesPrevious CD4Initial CD4Mean changeOutcome measuresCD4Animal studiesDrug AdministrationEast BaltimoreDrug typeCells xLymphocytesInjection frequencyOutreach techniques
1996
Temporal Trends of Initial CD4 Cell Counts Following Human Immunodeficiency Virus Seroconversion in Italy, 1985–1992
Galai N, Lepri A, Vlahov D, Pezzotti P, Sinicco A, Rezza G, Study H. Temporal Trends of Initial CD4 Cell Counts Following Human Immunodeficiency Virus Seroconversion in Italy, 1985–1992. American Journal Of Epidemiology 1996, 143: 278-282. PMID: 8561162, DOI: 10.1093/oxfordjournals.aje.a008739.Peer-Reviewed Original ResearchConceptsCD4 cell measurementsInitial CD4 cell countHuman immunodeficiency virus (HIV) seroconversionCD4 cell countCell countCD4 cell count increaseItalian Seroconversion StudyLow CD4 countMonths of seroconversionYear of seroconversionCD4 cell levelsCell count increaseMedian lag timeCD4 countCD4 levelsHIV seroconversionPositive serologyNegative serologyHIV seroconvertersClinical centersRisk groupsSeroconversion StudySeroconversionMultivariate modelLag time
1992
Effect of Chronic Substance Abuse on the Neuropsychological Performance of Intravenous Drug Users with a High Prevalence of HIV-1 Seropositivity
Concha M, Graham N, Muñoz A, Vlahov D, Royal W, Updike M, Nance-Sproson T, Seines O, McArthur J. Effect of Chronic Substance Abuse on the Neuropsychological Performance of Intravenous Drug Users with a High Prevalence of HIV-1 Seropositivity. American Journal Of Epidemiology 1992, 136: 1338-1348. PMID: 1362630, DOI: 10.1093/oxfordjournals.aje.a116446.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBaltimoreBlack or African AmericanCD4-Positive T-LymphocytesChronic DiseaseCognition DisordersConfounding Factors, EpidemiologicEducational StatusEmploymentEvaluation Studies as TopicFemaleHIV SeropositivityHIV SeroprevalenceHIV-1HumansLeukocyte CountLinear ModelsMaleMass ScreeningNeuropsychological TestsPopulation SurveillancePredictive Value of TestsPrisonsPsychomotor PerformanceSubstance Abuse, IntravenousConceptsNeuropsychological test performanceHIV-1 seropositivityIntravenous drug usersTest performanceNeuropsychological performancePractice effectsHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersVirus type 1 infectionSubstance abuseSignificant practice effectsHIV-1 serostatusType 1 infectionIntravenous Experience (ALIVE) studyFrequency of drugChronic substance abuseNeuropsychological functioningCognitive performanceImmunodeficiency syndromeAsymptomatic stageHigh prevalenceOutcome measuresDrug useIntoxicated individualsMultivariate analysis